The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Open accessAbstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, because, while seemingly infrequent, it is often fulminant and lethal. The underlying basis of ICI-associated myocarditis is not completely understood. While the importance of T cells is clear, the inciting antigens, why they are recognized, and the mechanisms leading to cardiac cell injury remain poorly characterized. These issues underscore the need for basic and clinical studies to define pathogenesis, identify predictive biomarkers, improve diagnostic strategies, and develop effective treatments. An improved understanding of ICI-associated myocarditis will provide insights into the equilibrium between the immune and cardiovascular systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This discovery suggests a potential involvement of autoreactive T cells targeting α -MyHC in the initiation and progression of other forms of myocarditis.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent cases of ICI myocarditis have expanded our insights into the role of α -MyHC-specific T cells in myocarditis development. 41-46”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ICI myocarditis emerges as an infrequent but potentially fatal condition associated with ICI therapies, especially when used in combination”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“PD-1 and PD-L1 blockers mediated similar responses in patients with advanced and otherwise untreatable melanoma, non–small cell lung carcinoma, and urothelial tumors (77, 78).”
BackgroundCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationCD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., Liao, P., Lang, X., Kryczek, I., Sell, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1170-y · Cited by 2,880
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Self-citationChimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Self-citationFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Self-citationCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072
Self-citationTowards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Self-citationKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Harding, F., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,558
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,525
Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)
Klein, L., Kyewski, B., Allen, P. M., & Hogquist, K. A. (2014) · Nature reviews. Immunology · doi:10.1038/nri3667 · Cited by 1,508
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,372
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Self-citationAutoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.
Asano, M., Toda, M., Sakaguchi, N., & Sakaguchi, S. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.2.387 · Cited by 1,328
Perforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327
Myocarditis. A histopathologic definition and classification.
Aretz, H. T., Billingham, M. E., Edwards, W. D., Factor, S. M., Fallon, J. T., Fenoglio, J. J., Olsen, E. G. J., & Schöen, F. J. (1987) · PubMed · Cited by 1,307
Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271
Self-citationTissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,244
Self-citationLinette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,209
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,181
CD8+ T Cells: Foot Soldiers of the Immune System
Zhang, N., & Bevan, M. J. (2011) · Immunity · doi:10.1016/j.immuni.2011.07.010 · Cited by 1,157
Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg
Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., MONTAG, A. G., Brady, W., Gibson, M. G., Linsley, P. S., & Bluestone, J. A. (1992) · Science · doi:10.1126/science.1323143 · Cited by 1,121
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 1,006
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Re, D. P. D., Amgalan, D., Linkermann, A., Liu, Q., & Kitsis, R. N. (2019) · Physiological Reviews · doi:10.1152/physrev.00022.2018 · Cited by 994
Self-citationIncreased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
Self-citationCD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · cited 2×
“In contrast to priming, these later activation steps require only TCR engagement by antigen/MHC, although they are amplified by other costimulatory signals (30).”
BackgroundLAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixerás, E., Roman‐Roman, S., Genevée, C., Viégas-Pèquignot, E., & Hercend, T. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.5.1393 · Cited by 936
Cardioimmunology: the immune system in cardiac homeostasis and disease
Świrski, F. K., & Nahrendorf, M. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0065-8 · Cited by 905
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J., Tran, D. Q., Stoddard, J. L., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 879
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N. B., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 877
Self-citationOkazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 873
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 867
Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G. A. N., Durrant, I. J., Luger, S. M., Marks, D. I., FRANKLIN, I. M., et al. (2006) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Ammirati, E., Frigerio, M., Adler, E. D., Basso, C., Birnie, D. H., Brambatti, M., Friedrich, M. G., Klingel, K., Lehtonen, J., Moslehi, J. J., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007405 · Cited by 811
Self-citationPattern Recognition Receptors and the Host Cell Death Molecular Machinery
Amarante-Mendes, G. P., Adjemian, S., Branco, L. M., Zanetti, L. C., Weinlich, R., & Bortoluci, K. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02379 · Cited by 802
Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule
Linsley, P. S., Wallace, P. M., Johnson, J., Gibson, M. G., Greene, J. L., Ledbetter, J. A., Singh, C., & Tepper, M. A. (1992) · Science · doi:10.1126/science.1496399 · Cited by 790
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Martínez‐Lostao, L., Anel, A., & Pardo, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0685 · Cited by 766
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726
Cameron, B., Gerry, A. B., Dukes, J. D., Harper, J. V., Kannan, V., Bianchi, F., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 703
Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689
The Interaction Properties of Costimulatory Molecules Revisited
Collins, A. V., Brodie, D. W., Gilbert, R. J. C., Iaboni, A., Manso-Sancho, R., Walse, B., Stuart, D. I., van der Merwe, P. A., & Davis, S. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00362-x · Cited by 675
Viral myocarditis—diagnosis, treatment options, and current controversies
Pollack, A., Kontorovich, A. R., Fuster, V., & Dec, G. W. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.108 · Cited by 657
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 652
Self-citationImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Kociol, R. D., Cooper, L. T., Fang, J. C., Moslehi, J. J., Pang, P. S., Sabe, M. A., Shah, R. V., Sims, D. B., Thiene, G., Vardeny, O., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000745 · Cited by 625
Self-citationJackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Drobni, Z. D., Alvi, R. M., Taron, J., Zafar, A., Murphy, S., Rambarat, P. K., Mosarla, R. C., Lee, C., Zlotoff, D. A., Raghu, V. K., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049981 · Cited by 590
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley, P. S., Greene, J. L., Tan, P., Bradshaw, J., Ledbetter, J. A., Anasetti, C., & Damle, N. K. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.6.1595 · Cited by 581
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Self-citationCoinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 560
Self-citationInhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 559
CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., & Davis, S. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.393 · Cited by 551
Baughman, K. L. (2006) · Circulation · doi:10.1161/circulationaha.105.589663 · Cited by 543
Cardiac myosin induces myocarditis in genetically predisposed mice.
Neu, N., Rose, N. R., Beisel, K. W., Herskowitz, A., Gurri-Glass, G., & Craig, S. W. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.11.3630 · Cited by 523
Negative selection — clearing out the bad apples from the T-cell repertoire
Palmer, E. (2003) · Nature reviews. Immunology · doi:10.1038/nri1085 · Cited by 520
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
Escudier, M., Cautela, J., Malissen, N., Ancédy, Y., Orabona, M., Pinto, J., Monestier, S., Grob, J., Scemama, U., Jacquier, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030571 · Cited by 516
Cardiovascular toxicities associated with immune checkpoint inhibitors
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508
Self-citationLineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice
Singer, A., Adoro, S., & Park, J. (2008) · Nature reviews. Immunology · doi:10.1038/nri2416 · Cited by 497
Myocarditis in the Setting of Cancer Therapeutics
Bonaca, M. P., Olenchock, B. A., Salem, J., Wiviott, S. D., Éderhy, S., Cohen, A. A., Stewart, G. C., Choueiri, T. K., Carli, M. F. D., Allenbach, Y., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.034497 · Cited by 473
Self-citationAbatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1901677 · Cited by 443
Self-citationDissecting the mechanisms of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0275-8 · Cited by 436
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner-Weinzierl, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., & Lin, Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.210 · Cited by 382
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun‐Vignes, B., Mammen, A. L., Moslehi, J. J., & Salem, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 382
Self-citationCardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Alvi, R. M., Frigault, M. J., Fradley, M. G., Jain, M. D., Mahmood, S., Awadalla, M., Lee, D. H., Zlotoff, D. A., Zhang, L., Drobni, Z. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.038 · Cited by 367
Myosin-induced acute myocarditis is a T cell-mediated disease.
Smith, S. C., & Allen, P. (1991) · Journal of Immunology · doi:10.4049/jimmunol.147.7.2141 · Cited by 360
Sharpe, A. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00784.x · Cited by 359
Self-citationJenkins, M. K., Chen, C., Jung, G., Mueller, D. L., & Schwartz, R. H. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.1.16 · Cited by 355
Selection of Self-Reactive T Cells in the Thymus
Stritesky, G. L., Jameson, S. C., & Hogquist, K. A. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075035 · Cited by 350
Gay, D. L., Maddon, P. J., Sékaly, R., Talle, M. A., Godfrey, M., Long, E. O., Goldstein, G., Chess, L., Axel, R., Kappler, J. W., et al. (1987) · Nature · doi:10.1038/328626a0 · Cited by 345
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Okazaki, T., Okazaki, I., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 339
Decision checkpoints in the thymus
Carpenter, A. C., & Bosselut, R. (2010) · Nature Immunology · doi:10.1038/ni.1887 · Cited by 335
Kodama, M., Matsumoto, Y., Fujiwara, M., Masani, F., Izumi, T., & Shibata, A. (1990) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(90)90039-s · Cited by 330
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303
Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 + T-Cell–Mediated Injury in the Heart
Grabie, N., Gotsman, I., DaCosta, R., Pang, H. B., Stavrakis, G., Butte, M. J., Keir, M. E., Freeman, G. J., Sharpe, A. H., & Lichtman, A. H. (2007) · Circulation · doi:10.1161/circulationaha.107.709360 · Cited by 291
Self-citationWei, S. C., Meijers, W. C., Axelrod, M. L., Anang, N.-A. A. S., Screever, E. M., Wescott, E. C., Johnson, D. B., Whitley, E., Lehmann, L., Courand, P.-Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0856 · Cited by 290
Self-citationPD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288
Self-citationZhang, L., Zlotoff, D. A., Awadalla, M., Mahmood, S., Nohria, A., Hassan, M. Z. O., Thuny, F., Zubiri, L., Chen, C. L., Sullivan, R. J., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044703 · Cited by 285
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells
Eppihimer, M., Gunn, J., Freeman, G., Greenfield, E., Chernova, T., Erickson, J., & Leonard, J. (2002) · Microcirculation · doi:10.1080/713774061 · Cited by 272
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
Tan, C. L., Kuchroo, J. R., Sage, P. T., Liang, D., Francisco, L. M., Buck, J. N., Thaker, Y. R., Zhang, Q., McArdel, S. L., Juneja, V. R., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20182232 · Cited by 269
Self-citationPD-1 deficiency results in the development of fatal myocarditis in MRL mice
Wang, J., Okazaki, I., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 268
Caforio, A. L. P., Adler, Y., Agostini, C., Allanore, Y., Anastasakis, A., Arad, M., Böhm, M., Charron, P., Elliot, P. M., Eriksson, U., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx321 · Cited by 264
Immuno-oncology drug development goes global
Yu, J. X., Hubbard-Lucey, V. M., & Tang, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00167-9 · Cited by 262
Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy
Gil-Cruz, C., Perez-Shibayama, C., De Martin, A., Ronchi, F., van der Borght, K., Niederer, R., Onder, L., Lütge, M., Novkovic, M., Nindl, V., et al. (2019) · Science · doi:10.1126/science.aav3487 · Cited by 260
Immune Checkpoint Inhibitor Toxicity in 2018
Johnson, D. B., Chandra, S., & Sosman, J. A. (2018) · JAMA · doi:10.1001/jama.2018.13995 · Cited by 239
Cardiac myosin-Th17 responses promote heart failure in human myocarditis
Myers, J. M., Cooper, L. T., Kem, D. C., Stavrakis, S., Kosanke, S. D., Shevach, E. M., Fairweather, D., Stoner, J. A., Cox, C. J., & Cunningham, M. W. (2016) · JCI Insight · doi:10.1172/jci.insight.85851 · Cited by 230
Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans
Lv, H., Havari, E., Pinto, S., Gottumukkala, R. V. S. R. K., Cornivelli, L., Raddassi, K., Matsui, T., Rosenzweig, A., Bronson, R. T., Smith, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44583 · Cited by 228
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903064 · Cited by 224
Chapter 4 Pathogenesis of Myocarditis and Dilated Cardiomyopathy
Cihakova, D., & Rose, N. R. (2008) · Advances in Immunology · doi:10.1016/s0065-2776(08)00604-4 · Cited by 223
Zhao, Y., Bennett, A., Zheng, Z., Wang, Q. J., Robbins, P. F., Yu, L., Li, Y., Molloy, P. E., Dunn, S. M., Jakobsen, B. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5845 · Cited by 221
Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
Deutsch, É., Chargari, C., Galluzzi, L., & Kroemer, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30171-8 · Cited by 216
Self-citationImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Self-citationMyosin: A Link Between Streptococci and Heart
Krisher, K., & Cunningham, M. W. (1985) · Science · doi:10.1126/science.2578225 · Cited by 211
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies
Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben‐Yehuda, O., & Moslehi, J. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 208
Self-citationSmoldering myocarditis following immune checkpoint blockade
Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L. J., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0296-4 · Cited by 202
Self-citationImmune Checkpoint Inhibitor–Associated Myositis
Anquetil, C., Salem, J., Lebrun‐Vignes, B., Johnson, D. B., Mammen, A. L., Stenzel, W., Léonard-Louis, S., Benvéniste, O., Moslehi, J. J., & Allenbach, Y. (2018) · Circulation · doi:10.1161/circulationaha.118.035898 · Cited by 200
Self-citationLucas, J. A., Weinmann‐Menke, J., Rabacal, W., Schöen, F. J., Sharpe, A. H., & Kelley, V. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2513 · Cited by 196
Self-citationCardiovascular Effects of CAR T Cell Therapy
Lefebvre, B., Kang, Y., Smith, A. M., Frey, N. V., Carver, J. R., & Scherrer‐Crosbie, M. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.04.012 · Cited by 177
Cunningham, M. W., Antone, S. M., Gulizia, J. M., McManus, B. M., Fischetti, V. A., & Gauntt, C. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1320 · Cited by 175
Allenbach, Y., Anquetil, C., Manouchehri, A., Benvéniste, O., Lambotte, O., Lebrun‐Vignes, B., Spano, J., Éderhy, S., Klatzmann, D., Rosenzwajg, M., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102586 · Cited by 163
Self-citationCardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Self-citationMimicry and Antibody-Mediated Cell Signaling in Autoimmune Myocarditis
Li, Y., Heuser, J. S., Cunningham, L. C., Kosanke, S. D., & Cunningham, M. W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8234 · Cited by 155
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
Eppihimer, M. J., Gunn, J., Freeman, G. J., Greenfield, E. A., Chernova, T., Erickson, J., & Leonard, J. P. (2002) · PubMed · doi:10.1038/sj/mn/7800123 · Cited by 149
Nindl, V., Maier, R., Ratering, D., de Giuli, R., Züst, R., Thiel, V., Scandella, E., Padova, F. D., Köpf, M., Rudin, M., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201142209 · Cited by 144
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
Engelhardt, J., Sullivan, T. J., & Allison, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1052 · Cited by 142
Donermeyer, D. L., Beisel, K. W., Allen, P. M., & Smith, S. C. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1291 · Cited by 140
Ganatra, S., Redd, R. A., Hayek, S. S., Parikh, R. B., Azam, T. U., Yanik, G. A., Spendley, L. N., Nikiforow, S., Jacobson, C. A., & Nohria, A. (2020) · Circulation · doi:10.1161/circulationaha.120.048100 · Cited by 134
T cell checkpoint regulators in the heart
Grabie, N., Lichtman, A. H., & Padera, R. F. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz025 · Cited by 126
Self-citationBellinger, A. M., Arteaga, C. L., Force, T. L., Humphreys, B. D., Demetri, G. D., Druker, B. J., & Moslehi, J. J. (2015) · Circulation · doi:10.1161/circulationaha.115.010484 · Cited by 119
Self-citationTIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
Fucikova, J. P., Raková, J., Hensler, M., Kašíková, L., Belicova, L., Hladíková, K., Truxová, I., Škapa, P., Laco, J., Pecen, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4175 · Cited by 119
Self-citationTay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Self-citationCutting Edge: Cardiac Myosin Activates Innate Immune Responses through TLRs
Zhang, P., Cox, C. J., Alvarez, K. M., & Cunningham, M. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800861 · Cited by 117
Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107
Self-citationTakotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors
Éderhy, S., Cautela, J., Ancédy, Y., Escudier, M., Thuny, F., & Cohen, A. A. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2017.11.036 · Cited by 104
Dynamic Tuning of Lymphocytes: Physiological Basis, Mechanisms, and Function
Grossman, Z., & Paul, W. E. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100027 · Cited by 101
Historical Overview of Immunological TolerancePreprint
Schwartz, R. H. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006908 · Cited by 99
Galvin, J. E., Hemric, M. E., Kosanke, S. D., Factor, S. M., Quinn, A., & Cunningham, M. W. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64373-8 · Cited by 99
Stavrakis, S., Yu, X., Patterson, E. S., Huang, S., Hamlett, S., Chalmers, L. J., Pappy, R. M., Cunningham, M. W., MORSHED, S. A., Davies, T. F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.015 · Cited by 98
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Géraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck‐Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 97
Self-citationSurvival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors
Arangalage, D., Delyon, J., Lermuzeaux, M., Ekpe, K., Éderhy, S., Pagès, C., & Lebbé, C. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0396 · Cited by 86
Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies
Mascaro-Blanco, A., Alvarez, K., Yu, X., Lindenfeld, J., Olansky, L., Lyons, T., Duvall, D., Heuser, J. S., Gosmanova, A., Rubenstein, C. J., et al. (2008) · Autoimmunity · doi:10.1080/08916930802031579 · Cited by 86
The heart of the matter: Protection of the myocardium from T cells
Lichtman, A. H. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.05.004 · Cited by 84
Self-citationCancer-Drug Discovery and Cardiovascular Surveillance
Groarke, J. D., Cheng, S., & Moslehi, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1313140 · Cited by 83
Self-citationDevelopment of CD4−CD8+ cytotoxic T cells requires interactions with class I MHC determinants
Marusić-Galesić, S., Stephany, D., Longo, D. L., & Kruisbeek, A. M. (1988) · Nature · doi:10.1038/333180a0 · Cited by 77
Waliany, S., Lee, D. C., Witteles, R. M., Neal, J. W., Nguyen, P. K. P., Davis, M. M., Salem, J., Wu, S. M., Moslehi, J. J., & Zhu, H. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 77
Self-citationReversible Cardiomyopathy Associated with Sunitinib and Sorafenib
Uraizee, I., Cheng, S. C., & Moslehi, J. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1108849 · Cited by 71
Self-citationThe Cardiovascular Perils of Cancer Survivorship
Moslehi, J. J. (2013) · New England Journal of Medicine · doi:10.1056/nejme1215300 · Cited by 69
Self-citationShah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0986 · Cited by 64
Self-citationMangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Self-citationMahmood, S., Chen, C. L., Shapnik, N., Krishnan, U., Singh, H. S., & Makker, V. (2018) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2018.05.014 · Cited by 55
T Cells and Regulated Cell Death
Spetz, J. K. E., Presser, A. G., & Sarosiek, K. A. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.07.004 · Cited by 55
Kania, G., Siegert, S., Behnke, S., Prados‐Rosales, R., Casadevall, A., Lüscher, T. F., Luther, S. A., Köpf, M., Eriksson, U., & Błyszczuk, P. (2013) · Circulation · doi:10.1161/circulationaha.112.000434 · Cited by 51
Autoimmunity in viral myocarditis
Reddy, J., Massilamany, C., Buskiewicz, I., & Huber, S. A. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283620036 · Cited by 50
Chuy, K. L., Oikonomou, E. K., Postow, M. A., Callahan, M. K., Chapman, P. B., Shoushtari, A. N., Neilan, T. G., Fradley, M. G., Ramanathan, L. V., Wolchok, J. D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0040 · Cited by 44
Huber, S. A., Moraska, A. F., & Cunningham, M. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5543 · Cited by 44
Sheng, C. C., Amiri‐Kordestani, L., Palmby, T. R., Force, T. L., Hong, C. C., Wu, J. C., Croce, K., Kim, G., & Moslehi, J. J. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.05.008 · Cited by 40
Self-citationCardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T)
Salem, J., Éderhy, S., Lebrun‐Vignes, B., & Moslehi, J. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.070 · Cited by 38
Self-citationRelevance of Molecular Mimicry in the Mediation of Infectious Myocarditis
Massilamany, C., Huber, S. A., Cunningham, M. W., & Reddy, J. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9519-3 · Cited by 36
Moey, M., Gougis, P., Goldschmidt, V., Johnson, D. B., Lebrun‐Vignes, B., Moslehi, J. J., Cadranel, J. L., & Salem, J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00038-2020 · Cited by 36
Self-citationStimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies
Han, X. N., & Vesely, M. D. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.07.003 · Cited by 30
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors
Vozy, A., Martin, E. D., Johnson, D. B., Lebrun‐Vignes, B., Moslehi, J. J., & Salem, J. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.022 · Cited by 27
Self-citationMoslehi, J. J., Brinkley, D. M., & Meijers, W. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.05.026 · Cited by 17
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 736
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 389
Self-citationT cells specific for α-myosin drive immunotherapy-related myocarditis
Axelrod, M. L., Meijers, W. C., Screever, E. M., Qin, J., Carroll, M. G., Sun, X., Tannous, E., Zhang, Y., Sugiura, A., Taylor, B. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05432-3 · Cited by 367
Self-citationDeep insight into cytokine storm: from pathogenesis to treatment
Nie, J., Zhou, L., Tian, W., Liu, X., Yang, L., Yang, X., Zhang, Y., Wei, S., Wang, D. W., & Wei, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02178-y · Cited by 251
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 203
Self-citation
Metadata
- Authors
- Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N.
- Affiliations
- Vanderbilt University Medical Center (US)
- Brigham and Women's Hospital (US)
- Université Paris Cité (FR)
- Albert Einstein College of Medicine (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2021-03-01
- Volume
- 131
- Issue
- 5
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7919710
- OpenAlex
- W3134997217
- Cited by
- 237
- References
- 181
- Citations by year
- 2026: 60 · 2025: 46 · 2024: 46 · 2023: 32 · 2022: 40 · 2021: 13
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (PR191593)
- American Heart Association (18SRG34280018)
- Vanderbilt University
- Vanderbilt University Medical Center
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL131862, R01HL130861, R01HL141466, R01HL138475)
- National Institute of Allergy and Infectious Diseases (P01AI056299, P01AI039671)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, T cell-mediated inflammation, predictive biomarkers, diagnostic approach, cancer immunotherapy toxicity
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Myocarditis, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
